Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 57, Issue 18, Pages 4840-4848Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201710407
Keywords
antitumor agents; protein-protein interactions; PD-1; PD-L1; protein structures
Categories
Funding
- National Institute of Health (NIH) [2R01GM097082-05]
- European Lead Factory (IMI) [115489]
- Qatar National Research Foundation [NPRP6-065-3-012]
- National Science Centre, Poland [UMO-2012/06/A/ST5/00224, UMO-2014/12/W/NZ1/00457]
- ITN Accelerated Early stage drug dIScovery (AEGIS) [675555]
- COFUND ALERT [665250]
- KWF Kankerbestrijding grant [10504]
Ask authors/readers for more resources
The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
